Abstract:OBJECTIVETo produce a new bone tissue engineered carrier through combination of xenograft bone (X) and sodium alginate (A) and to investigate the biological character of the cells in the carrier and the ability of bone-forming in vivo, so as to provide experimental evidence for a more effective carrier.METHODSBMSCs were extracted from 2-week-old New Zealand rabbits and the BMSCs were induced by rhBMP-2 (1 x 10(-8)mol/L). The second generation of the induced BMSCs was combined with 1% (V/W) A by final concentration of 1 x 10(5)/mL. After 4-day culture, cells in gel were investigated by HE staining. The second generation of the induced BMSCs was divided into the DMEM gel group and the DMEM containing 1% A group. They were seeded into 48 well-cultivated cell clusters by final concentration of 1 x 10(5)/mL. Seven days later, the BMP-2 expressions of BMSCs in A and in commonly-cultivated cells were compared. The second generation of the induced BMSCs was mixed with 2% A DMEM at a final concentration of 1 x 10(10)/mL. Then it was compounded with the no antigen X under negative pressure. After 4 days, cells growth was observed under SEM. Twenty-four nude mice were randomly divided into 2 groups (n = 12). The compound of BMSCs-A-X (experimental group) and BMSCs-X (control group) with BMSCs whose final concentration was 1 x 10(10)/mL was implanted in muscles of nude mice. Bone formation of the compound was histologically evaluated by Image Analysis System 2 and 4 weeks after the operation, respectively.RESULTSCells suspended in A and grew plump. Cell division and nuclear fission were found. Under the microscope, normal proliferation, many forming processes, larger nucleus, clear nucleolus and more nuclear fission could be seen. BMP-2 expression in the DMEM gel group was 44.10% +/- 3.02% and in the DMEM containing 1% A group was 42.40% +/- 4.83%. There was no statistically significant difference between the two groups (P > 0.05). A was compounded evenly in the micropore of X and cells suspended in A 3-dimensionally with matrix secretion. At 2 weeks after the implantation, according to Image Analysis System, the compound of BMSCs-A-X was 5.26% +/- 0.24% of the total area and the cartilage-like tissue was 7.31% +/- 0.32% in the experimental group; the compound of BMSCs-X was 2.16% +/- 0.22% of the total area and the cartilage-like tissue was 2.31% +/- 0.21% in the control group. There was statistically significant difference between the two groups (P < 0.05). At 4 weeks after the operation, the compound of BMSCs-A-X was 7.26% +/- 0.26% of the total area and the cartilage-like tissue was 9.31% +/- 0.31% in the experimental group; the compound of BMSCs-X was 2.26% +/- 0.28% of the total area and the cartilage-like tissue was 3.31% +/- 0.26% in the control group. There was statistically significant difference between the two groups (P < 0.05).CONCLUSIONThe new carrier compounding A and no antigen X conforms to the superstructural principle of tissue engineering, with maximum cells load. BMSCs behave well in the compound carrier with efficient bone formation in vivo.

Xenographic bone graft materials safely prepared by compound surfactant

Preparation and biological safety of compound surfactant treated bio-derived bone implantation material

Experimental study on xenogeneic bone prepared with deproteinization and freeze-drying method

Antigenicity and biocompatibility of acellular xenogeneic cancellous bone prepared by ultrasonic biotechnology

Effects of a bone graft substitute consisting of porous gradient HA/ZrO 2 and gelatin/chitosan slow-release hydrogel containing BMP-2 and BMSCs on lumbar vertebral defect repair in rhesus monkey.

Biocompatibility Evaluation of a Bone Graft Material-Poly (amino Acids)/calcium Sulfate Composite

Preliminary Animal Study on Bone Formation Ability of Commercialized Particle-Type Bone Graft with Increased Operability by Hydrogel

[Histological structure and cytocompatibility of novel acellular bone matrix scaffold].

Hydroxyapatite nanoparticle-modified porous bone grafts with improved cell attachment

[Carrier Combination of Tissue Engineered Bone by Sodium Alginate and Xenograft Bone and Bone Formation in Vivo].

Evaluation of a novel reconstituted bone xenograft using processed bovine cancellous bone in combination with purified bovine bone morphogenetic protein.

[Histological Observation of Bio-Derived Bone Prepared by Different Methods after Implantation].

Biocompatibility of novel bionic scaffold with nanostructure

Characterization and osteoblast-like cell compatibility of porous scaffolds: bovine hydroxyapatite and novel hydroxyapatite artificial bone

In vitro assessment of bovine-derived hydroxyapatite for bone xenografts

Preparation and characterization of two novel osteoinductive fishbone-derived biphasic calcium phosphate bone graft substitutes

Preparation of tissue engineered bone and in vivo osteogenesis using alginate and xenograft bone composite technology

Biomechanic characteristics and adhesion performance of bovine acellular bone matrix

Cell compatibility of two novel scaffold materials

Biotin-avidin Mediates the Binding of Adipose-Derived Stem Cells to a Porous Β-Tricalcium Phosphate Scaffold: Mandibular Regeneration

An Injectable Hydrogel as Bone Graft Material with Added Antimicrobial Properties